PTC Therapeutics, Inc.PTCTNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-11.36%
↓ 316% below average
Average (39q)
5.25%
Historical baseline
Range
High:95.91%
Low:-47.32%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -11.36% |
| Q2 2025 | 3.69% |
| Q1 2025 | -12.66% |
| Q4 2024 | -22.70% |
| Q3 2024 | 22.13% |
| Q2 2024 | 13.81% |
| Q1 2024 | -4.30% |
| Q4 2023 | -26.10% |
| Q3 2023 | -11.65% |
| Q2 2023 | -4.74% |
| Q1 2023 | 3.41% |
| Q4 2022 | 14.04% |
| Q3 2022 | 5.21% |
| Q2 2022 | 12.27% |
| Q1 2022 | -6.52% |
| Q4 2021 | 14.52% |
| Q3 2021 | 4.27% |
| Q2 2021 | -6.71% |
| Q1 2021 | 13.98% |
| Q4 2020 | 26.90% |
| Q3 2020 | -47.32% |
| Q2 2020 | 95.91% |
| Q1 2020 | 10.11% |
| Q4 2019 | 29.73% |
| Q3 2019 | 5.16% |
| Q2 2019 | 14.10% |
| Q1 2019 | -2.02% |
| Q4 2018 | -1.33% |
| Q3 2018 | 66.74% |
| Q2 2018 | 3.97% |
| Q1 2018 | 7.28% |
| Q4 2017 | -2.63% |
| Q3 2017 | -2.63% |
| Q2 2017 | 12.69% |
| Q1 2017 | 5.20% |
| Q4 2016 | -17.15% |
| Q3 2016 | 8.91% |
| Q2 2016 | -8.19% |
| Q1 2016 | -10.41% |
| Q4 2015 | 14.39% |